Veenstra, V. L.
Damhofer, H.
Waasdorp, C.
van Rijssen, L. B.
van de Vijver, M. J.
Dijk, F.
Wilmink, H. W.
Besselink, M. G.
Busch, O. R.
Chang, D. K.
Bailey, P. J.
Biankin, A. V.
Kocher, H. M.
Medema, J. P.
Li, J. S.
Jiang, R.
Pierce, D. W.
van Laarhoven, H. W. M.
Bijlsma, M. F.
Article History
Received: 24 August 2018
Revised: 9 October 2018
Accepted: 24 October 2018
First Online: 16 November 2018
Conflict of interest
: M.F.B. has received research funding from Celgene. H.W.L. has acted as a consultant for Celgene, Eli Lilly and Company, Nordic Pharma Group and Philips, has received research grants from, Amgen, Bayer Schering Pharma AG, Celgene, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Nordic Pharma Group, Philips, Roche Pharmaceuticals. D.W.P., R.J., and J.S.L. are Celgene employees. Other than Celgene, none were involved in drafting of the manuscript.